Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK4 | Q9P2K8 | 13/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15194239 | 0.94 | EIF2AK4 (0.42) | EIF2AK4USP30NTRK1HDAC4HDAC6 | |
| SCHEMBL15194240 | 0.94 | EIF2AK4 (0.42) | EIF2AK4USP30NTRK1HDAC4HDAC6 | |
| SCHEMBL15194229 | 0.92 | EIF2AK4 (0.44) | EIF2AK4USP30NTRK1HDAC4HDAC6 | |
| SCHEMBL15199775 | 0.90 | USP30 (0.40) | EIF2AK4USP30NTRK1CKS1BSKP1 | |
| SCHEMBL15194281 | 0.88 | USP30 (0.41) | EIF2AK4USP30NTRK1HDAC4HDAC6 | |
| SCHEMBL15194278 | 0.88 | USP30 (0.41) | EIF2AK4USP30NTRK1HDAC4HDAC6 | |
| SCHEMBL2040086 | 0.88 | ADORA2A (0.43) | EIF2AK4 | |
| SCHEMBL2038025 | 0.88 | EIF2AK4 (0.42) | EIF2AK4USP30NTRK1HDAC4HDAC6 | |
| SCHEMBL2038024 | 0.88 | EIF2AK4 (0.42) | EIF2AK4USP30NTRK1HDAC4HDAC6 | |
| SCHEMBL15193655 | 0.88 | EIF2AK4 (0.39) | EIF2AK4USP30NTRK1HDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | EIF2AK4 211/4885USP30 2146/4885NTRK1 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.